We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Screening Test Detects Tropical Disease in Blood Donors

By LabMedica International staff writers
Posted on 10 May 2010
A screening test that detects antibodies to a lethal tropical parasite will help safeguard blood for transfusions and tissue and organ recipients.

The test is fully automated, and is highly sensitive and specific for the blood-borne parasite, Trypanosoma cruzi, the causative agent of Chagas diseases. It uses serum or plasma from donors of whole blood or blood components as well as from organ or tissue donors and detects antibodies to T. cruzi. The assay can be used to screen blood from the transplant donor whether the heart is still beating or even if it is not. It is not designed to be used with cord blood.

Image: Light micrograph of a section through clusters (small clumps of purple bodies) of Trypanosoma cruzi protozoans in the heart muscle of a patient suffering from Chagas disease (Photo courtesy of Sinclair Stammers / SPL).
Image: Light micrograph of a section through clusters (small clumps of purple bodies) of Trypanosoma cruzi protozoans in the heart muscle of a patient suffering from Chagas disease (Photo courtesy of Sinclair Stammers / SPL).

Manufactured by Abbott Laboratories (Abbot Park, IL, USA), the Abbott Prism Chagas test is a two-step sandwich chemiluminescent assay that uses recombinant parasite antigens coated on microparticles. The test kit also contains anti-human conjugate and alkaline hydrogen peroxide for generating the photons. The test has detected antibodies to the parasite in over 1,000 donors since testing was instituted in 2007.

Reports indicate that 1 in every 27,500 blood donors in the United States will test positive for Chagas Disease. Blood donations in the United States exceed 15 million a year. The test is highly specific and does not react with serum of patients infected with other tropical or sexually transmitted diseases. An estimated 8-11 million people are known to be suffering from Chagas Disease in Mexico, Central and South America. The disease progresses from an acute phase to a chronic one, and is often undetected. The parasite has a predilection for the internal organs, especially the heart.

Karen Midthun, M.D., acting director of the US Food and Drug Administration's Center for Biologics Evaluation and Research, (FDA; Silver Spring, MD, USA), said that "Screening for T. cruzi is an important safety measure to help protect our blood supply and help prevent the spread of Chagas disease." This second-generation test has received FDA approval.

Related Links:
Abbott Laboratories
US Food and Drug Administration



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Urine Analyzer
respons® UDS100
New
Nucleic Acid Purification Instrument
QIAsymphony Connect

Latest Hematology News

New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
10 May 2010  |   Hematology

New Automated Hemostasis Systems Become Available Across US Laboratories
10 May 2010  |   Hematology

Updated Ferritin Thresholds Improve Detection of Iron Deficiency
10 May 2010  |   Hematology